FDA clears Oridion's capnography device:
This article was originally published in Clinica
Oridion Systems has received US FDA 510(k) clearance to market its device for monitoring non-intubated patients during procedural sedation. The Smart CapnoLine O2 system can help alert caregivers to the earliest possible warning signs of potentially fatal adverse events that can develop during sedation, including apnoea, ventilatory depression and airway obstruction, says the Jerusalem, Israel firm. The device collects breath samples for carbon dioxide analysis from both the nose and mouth, while also supplying oxygen to the patients.